ILMN
Illumina, Inc.131.56
-3.36-2.49%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms momentum, adds placement details.
Q&A largely reaffirmed prepared remarks on clinical consumables momentum into 2026's double-digit to mid-teens growth, while detailing 200-240 NovaSeq X placements at 50-60 per quarter, mostly clinical. Management highlighted clinical expansion via larger panels and whole-genome sequencing as the key future driver over volume alone. Research funding uncertainty persists despite NIH signals, capping consumables at low-mid single digits. No competitive threats emerged; confident in full-workflow value versus cheap rivals. China dialogues hint at upside beyond $210-220M guide. BioInsight gains pharma traction for 1-2% '27 lift. Research recovery bears watching.
Key Stats
Market Cap
20.22BP/E (TTM)
29.50Basic EPS (TTM)
4.46Dividend Yield
0%Recent Filings
10-K
FY2025 results
Illumina posted flat Core Illumina revenue of $4.34B for FY2025 ended December 28, 2025, with consumables up 2% on high-throughput demand yet instruments down 4% from fewer mid/high-throughput shipments amid capital constraints. Q4 saw steady momentum as customers shifted to NovaSeq X, offsetting Greater China weakness down $65M y/y from unreliable entities listing, while gross margin slipped to 66.1% on tariffs and $23M intangible hit. Operating income fell to $807M after 2024's $456M legal gain, but cash flow strengthened to $1.08B on $850M net income. Share repurchases totaled $748M, leaving $643M authorized; revolver fully available. Backlog hit $738M. China sanctions threaten Q4 momentum.
8-K
Q4 revenue up 5%
Illumina posted Q4 2025 revenue of $1.16B, up 5% from 2024, while full-year revenue held flat at $4.34B. Ex-China revenue grew 8% in Q4 and 2% annually, signaling core strength. Momentum surged. Guides 2026 revenue to $4.5B-$4.6B, with SomaLogic adding 1.5%-2.0% but diluting EPS by $0.18 and margins by 100bps.
8-K
Illumina closes SomaLogic deal
Illumina completed its acquisition of SomaLogic and related assets from Standard BioTools on January 30, 2026, for $350 million cash, plus up to $75 million milestones and royalties. This bolsters proteomics capabilities, integrating aptamer tech with NGS for scalable multiomics insights. Integration risks loom large. Deal funded by cash on hand.
8-K
Illumina Q4 revenue up 5%
Illumina released preliminary Q4 2025 results, posting $1.155B revenue, up 5% from Q4 2024, while full-year revenue held flat at $4.34B. Ex-China revenue grew 7% in Q4 to $1.100B and 2% yearly to $4.10B. Non-GAAP diluted EPS ranged $1.27-$1.30 for Q4. Full results due February 5, 2026; figures preliminary.
8-K
CMO hire, CCO exit
Illumina announced Chief Commercial Officer Everett Cunningham's resignation effective January 16, 2026, to become CEO of a life science tools company; CEO Jacob Thaysen steps in as interim. The company appointed genomics veteran Dr. Eric Green as Chief Medical Officer effective February 2, 2026, to advance clinical genomics and precision medicine. Leadership shifts bolster medical strategy amid commercial transition.
IPO
Website
Employees
Sector
Industry
A
Agilent Technologies, Inc.
139.19-1.41
APDN
Applied DNA Sciences, Inc.
5.62+1.35
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
IDXG
Interpace Biosciences, Inc.
1.14-0.02
MYGN
Myriad Genetics, Inc.
6.88-0.11
PSNL
Personalis, Inc.
7.98-0.50
QGEN
Qiagen N.V.
45.01-0.43
TMO
Thermo Fisher Scientific Inc
570.16-5.75
TWST
Twist Bioscience Corporation
31.13+0.06